Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Immunotherapy of cancer in 2012
2012
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
2009
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
2007
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
2006
Therapeutic cancer vaccines: are we there yet?
2010
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Immunology and immunotherapy approaches for prostate cancer
2007
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
2005
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
2011
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Taming cancer by inducing immunity via dendritic cells
2007
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Dendritic cells in cancer immunotherapy
2010
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Improved Endpoints for Cancer Immunotherapy Trials
2010
Glycopeptide dendrimers, Part III—a review: Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases
2008
Immunity, Inflammation, and Cancer
2010 Standout
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
2016
Emerging Biological Principles of Metastasis
2017 Standout
Immunotherapy for prostate cancer
2006
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
2010
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
The Golden Age of Transfer Hydrogenation
2015 Standout
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Coinhibitory Pathways in Immunotherapy for Cancer
2016
State of the Art and Prospects in Metal–Organic Framework (MOF)-Based and MOF-Derived Nanocatalysis
2019 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
2014
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
The future of immune checkpoint therapy
2015 StandoutScienceNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Magnetically Recoverable Nanocatalysts
2011 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
2014
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Neoantigens in cancer immunotherapy
2015 StandoutScience
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014
Works of Natalie Sacks being referenced
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
2012
Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer
2006
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
2006
Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer
2008
A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC)
2004
Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC)
2005
A Phase 2 Study of an Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer
2004
A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC)
2006
Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer
2007